
Opinion|Videos|February 5, 2025
Treatment and Co-Management of mCRPC Patients with Aggressive Disease
Author(s)Jose De La Cerda III, MD, MPH
This video segment explores treatment approaches for PSMA-positive mCRPC patients, algorithms for monitoring liver dysfunction in advanced CRPC, and exciting advancements in mCRPC treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- If the patient is positive for prostate-specific membrane antigen (PSMA), how would you treat the patient?
- What is your algorithm for monitoring patients with liver dysfunction and advanced CRPC?
- What advances in treatment of mCRPC are you most excited about?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
Trial launches of molecular glue degrader plus apalutamide in mCRPC
5








